Skip to main content
Grant Details

Grant Number: 1R21CA242044-01A1 Interpret this number
Primary Investigator: Hershman, Dawn
Organization: Columbia University Health Sciences
Project Title: Delays in Acquisition of Oral Antineoplastic Agents
Fiscal Year: 2020


PROJECT SUMMARY Over the past few years there has been an accelerating expansion of oral anticancer drugs. These drugs are expensive and cost up to $10,000/month. To counteract increasing medication costs, pharmacy benefit plans have increased copayment rates, deductibles and increased preauthorization. We propose to define barriers to initiation and non-adherence to anticancer medications that are considerably more expensive and the acquisition is more complex that other cancer and non-cancer therapies. We propose conduct a prospective cohort study among a diverse population of cancer patients prescribed non-hormonal oral antineoplastic agents, to define barriers to acquisition, initiation and first prescription renewal and we will conduct semi-structured interviews on a subset of 30 participants. We hypothesize that the increasing costs and subsequent complexities in acquisition associated with oral medications results in delays and barriers to access due to the administrative burden on the practice. Our specific aims are (1) to determine the rate and factors associated with non-initiation of oral antineoplastic agents in a socioeconomically, racially and ethnically diverse cohort of 750 patients prescribed oral cancer therapy. (2) To define the time (days) to initiation of antineoplastic treatment and factors contributing to longer initiation time. (3) To examine factors related to early discontinuation of oral antineoplastic agents (<90 days) among those who initiate. (4) To explore patient perceptions on the medication acquisition process. The goal of this proposal is to define and characterize the extent of use of these new expensive oral therapies, as well as to determine human costs and insurance related factors associated with delays in initiation and early discontinuation. We will determine the extent to which financial factors contribute to disparities in use. Results will inform policies and assist with the design of interventions to improve the quality and safety of oral medication use in oncology care.


Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs.
Authors: Lichtenstein M.R.L. , Beauchemin M.P. , Raghunathan R. , Lee S. , Doshi S.D. , Law C. , Accordino M.K. , Elkin E.B. , Wright J.D. , Hershman D.L. .
Source: JCO oncology practice, 2024 Jan; 20(1), p. 85-92.
EPub date: 2023-11-30.
PMID: 38033273
Related Citations

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.
Authors: Choueiri T.K. , Labaki C. , Bakouny Z. , Hsu C.Y. , Schmidt A.L. , de Lima Lopes G. , Hwang C. , Singh S.R.K. , Jani C. , Weissmann L.B. , et al. .
Source: Lancet regional health. Americas, 2023 Mar; 19, p. 100445.
EPub date: 2023-02-13.
PMID: 36818595
Related Citations

Impact of a Hospital-Based Specialty Pharmacy in Partnership With a Care Coordination Organization on Time to Delivery and Receipt of Oral Anticancer Drugs.
Authors: Beauchemin M.P. , Lichtenstein M.R.L. , Raghunathan R. , Doshi S.D. , Lee S. , Law C. , Accordino M.K. , Elkin E.B. , Wright J.D. , Hershman D.L. .
Source: JCO oncology practice, 2023 Mar; 19(3), p. e326-e335.
EPub date: 2022-12-06.
PMID: 36473132
Related Citations

Factors Associated With Patients Not Receiving Oral Anticancer Drugs.
Authors: Doshi S.D. , Lichtenstein M.R.L. , Beauchemin M.P. , Raghunathan R. , Lee S. , Law C. , Accordino M.K. , Elkin E.B. , Wright J.D. , Hershman D.L. .
Source: JAMA network open, 2022-10-03; 5(10), p. e2236380.
EPub date: 2022-10-03.
PMID: 36227596
Related Citations

Back to Top